Bone Loss After Denosumab: Only Partial Protection with Zoledronate
被引:89
|
作者:
Reid, Ian R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand
Auckland Dist Hlth Board, Dept Endocrinol, Auckland, New Zealand
Univ Auckland, Fac Med & Hlth Sci, Private Bag 92019, Auckland, New ZealandUniv Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand
Reid, Ian R.
[1
,2
,3
]
Horne, Anne M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New ZealandUniv Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand
Horne, Anne M.
[1
]
论文数: 引用数:
h-index:
机构:
Mihov, Borislav
[1
]
Gamble, Gregory D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New ZealandUniv Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand
Gamble, Gregory D.
[1
]
机构:
[1] Univ Auckland, Dept Med, Fac Med & Hlth Sci, Auckland, New Zealand
[2] Auckland Dist Hlth Board, Dept Endocrinol, Auckland, New Zealand
[3] Univ Auckland, Fac Med & Hlth Sci, Private Bag 92019, Auckland, New Zealand
A case series of six women with postmenopausal osteoporosis who had received continuous denosumab for 7 years and were then given a single infusion of zoledronate (5 mg) is reported. During denosumab treatment, bone mineral density (BMD) in the spine increased 18.5% (P = 0.006), and total hip BMD by 6.9% (P = 0.03). Post-zoledronate BMDs were measured 18-23 months after treatment, and there were significant declines at each site (P (spine) = 0.043, P (hip) = 0.005). Spine BMD remained significantly above the pre-denosumab baseline (+9.3%, P = 0.003), but hip BMD was not significantly different from baseline (-2.9%). At the time of post-zoledronate BMD measurements, serum PINP levels were between 39 and 60 mu g/L (mean 52 mu g/L), suggesting that the zoledronate treatment had not adequately inhibited bone turnover. It is concluded that this regimen of zoledronate administration is not adequate to preserve the BMD gains that result from long-term denosumab treatment.
机构:
424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece
Anastasilakis, Athanasios D.
Makras, Polyzois
论文数: 0引用数: 0
h-index: 0
机构:
251 Hellen Air Force & VA Gen Hosp, Dept Endocrinol & Diabet, Athens, Greece
251 Hellen Air Force & VA Gen Hosp, Dept Med Res, Athens, Greece424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece
Makras, Polyzois
Polyzos, Stergios A.
论文数: 0引用数: 0
h-index: 0
机构:
Aristotle Univ Thessaloniki, Med Sch, Lab Pharmacol 1, Thessaloniki, Greece424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece
Polyzos, Stergios A.
Kumar, Ajay
论文数: 0引用数: 0
h-index: 0
机构:
Ansh Labs, Webster, TX USA424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece
Kumar, Ajay
Kalra, Bhanu
论文数: 0引用数: 0
h-index: 0
机构:
Ansh Labs, Webster, TX USA424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece
Kalra, Bhanu
Mantzoros, Christos S.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Med Sch, Boston VA Healthcare Syst, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA424 Gen Mil Hosp, Dept Endocrinol, Ring Rd,564 29 N Efkarpia, Thessaloniki, Greece